Our goal is to identify novel putative cancer targets for drug discovery, diagnostic and/or prognostic applications. For this purpose, we use a high-throughput screening technology, tissue microarrays (TMAs), together with in situdetection methods, i.e., RNA in situhybridization (ISH) and immunohistochemistry (IHC), to translate early discoveries into clinical applications. TMA screening allows:
- Validation of basic research findings through the rapid and simultaneous analysis of hundreds of patient samples.
- Assessment of the prevalence of candidate gene deregulation through comparative expression analysis of normal tumor tissues.
- Identification of candidate diagnostic and prognostic markers through the correlation of expression results with clinicopathological and follow-up data in patient cohorts.
- Validation of druggable targets based on extensive in situanalysis in tumor samples.
- Tissue processing, tissue sectioning, slide staining and in situanalyses (ISH, IHC, FISH, etc.).
- Pathology material storage.
- Generation of multi-tumor TMAs, sectioning and distribution.
- Target validation.
- Assistance with procedures and technical support.
- Pathology expertise.
- Clinical data correspondence.
- Complete molecular reports with image collection and data interpretation.
- Statistical analysis.
- Clinicopathological and molecular databases.
- Access to high density collections, case collections with extensive follow-up, and cancer-specific TMAs, on a collaborative basis.
- Maintenance and upkeep of space dedicated to mouse pathology and assistance to users.
- Establishment of a pipeline from tissue to section.
- Assistance with procedures and technical support (mostly IHC and ISH).
- Mouse registry (centralization and automation of data, storage, retrieval).
- Mouse pathology expertise.